CoChat
Sign Up
Cited by 78

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex

Hettich, Moritz M., Matthes, Frank, Ryan, Devon P., Griesche, Nadine, Schröder, Susanne, Dorn, Stephanie, Krauß, Sybille, Ehninger, Dan·2014·PLoS ONE
DOI 10.1371/journal.pone.0102420PMC PMC4099345
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0102420

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The likely mechanism behind metformin's effect is the reduction in BACE1 activity.

    “The likely mechanism behind this is the reduction in BACE1 activity in response to metformin treatment.”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [177]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. A Alzheimer, 1995, An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”, Clin Anat, 8, 429, 10.1002/ca.980080612 · DOI · Paper page
  2. YW Zhang, 2011, APP processing in Alzheimer’s disease, Mol Brain, 4, 3, 10.1186/1756-6606-4-3 · DOI · Paper page
  3. GM Shankar, 2009, Alzheimer’s disease: synaptic dysfunction and Abeta, Mol Neurodegener, 4, 48, 10.1186/1750-1326-4-48 · DOI · Paper page
  4. BD Bennett, 2000, Expression analysis of BACE2 in brain and peripheral tissues, J Biol Chem, 275, 20647, 10.1074/jbc.M002688200 · DOI · Paper page
  5. C Southan, 2013, A tale of two drug targets: the evolutionary history of BACE1 and BACE2, Front Genet, 4, 293, 10.3389/fgene.2013.00293 · DOI
  6. X Sun, 2006, BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome, FASEB J, 20, 1369, 10.1096/fj.05-5632com · DOI
  7. AD Alonso, 1997, Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau, Proc Natl Acad Sci USA, 94, 298, 10.1073/pnas.94.1.298 · DOI · Paper page
  8. CX Gong, 2005, Post-translational modifications of tau protein in Alzheimer’s disease, J Neural Transm, 112, 813, 10.1007/s00702-004-0221-0 · DOI · Paper page
  9. Q Tian, 2002, Role of serine/threonine protein phosphatase in Alzheimer’s disease, Neurosignals, 11, 262, 10.1159/000067425 · DOI
  10. AM Brands, 2005, The effects of type 1 diabetes on cognitive performance: a meta-analysis, Diabetes Care, 28, 726, 10.2337/diacare.28.3.726 · DOI · Paper page
  11. A Ott, 1999, Diabetes mellitus and the risk of dementia: The Rotterdam Study, Neurology, 53, 1937, 10.1212/WNL.53.9.1937 · DOI · Paper page
  12. L Bertrand, 2008, Insulin signalling in the heart, Cardiovasc Res, 79, 238, 10.1093/cvr/cvn093 · DOI
  13. B Ravikumar, 2010, Regulation of mammalian autophagy in physiology and pathophysiology, Physiol Rev, 90, 1383, 10.1152/physrev.00030.2009 · DOI
  14. L Fritsche, 2008, How insulin receptor substrate proteins regulate the metabolic capacity of the liver–implications for health and disease, Curr Med Chem, 15, 1316, 10.2174/092986708784534956 · DOI
  15. C O’Neill, 2012, Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer’s disease, Biochem Soc Trans, 40, 721, 10.1042/BST20120080 · DOI
  16. CG Jolivalt, 2008, Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer’s disease and correction by insulin, J Neurosci Res, 86, 3265, 10.1002/jnr.21787 · DOI
  17. ZG Li, 2007, Alzheimer-like changes in rat models of spontaneous diabetes, Diabetes, 56, 1817, 10.2337/db07-0171 · DOI
  18. D Kirpichnikov, 2002, Metformin: an update, Ann Intern Med, 137, 25, 10.7326/0003-4819-137-1-200207020-00009 · DOI · Paper page
  19. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, <etal>et al</etal>.. (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA. · DOI · Paper page
  20. A Trockenbacher, 2001, MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation, Nat Genet, 29, 287, 10.1038/ng762 · DOI
  21. B Aranda-Orgilles, 2011, Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1 is a sequence-dependent regulator of translation efficiency controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1), J Biol Chem, 286, 39945, 10.1074/jbc.M111.224451 · DOI
  22. S Krauss, 2013, Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex, Nat Commun, 4, 1511, 10.1038/ncomms2514 · DOI
  23. E Kickstein, 2010, Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling, Proc Natl Acad Sci USA, 107, 21830, 10.1073/pnas.0912793107 · DOI · Paper page
  24. Y Chen, 2009, Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription, Proc Natl Acad Sci USA, 106, 3907, 10.1073/pnas.0807991106 · DOI · Paper page
  25. J Wang, 2012, Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation, Cell Stem Cell, 11, 23, 10.1016/j.stem.2012.03.016 · DOI · Paper page
  26. J Li, 2012, Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice, Pharmacol Biochem Behav, 101, 564, 10.1016/j.pbb.2012.03.002 · DOI · Paper page
  27. B Aranda-Orgilles, 2008, The Opitz syndrome gene product MID1 assembles a microtubule-associated ribonucleoprotein complex, Hum Genet, 123, 163, 10.1007/s00439-007-0456-6 · DOI
  28. E Liu, 2011, Control of mTORC1 signaling by the Opitz syndrome protein MID1, Proc Natl Acad Sci USA, 108, 8680, 10.1073/pnas.1100131108 · DOI
  29. S Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016 · DOI · Paper page
  30. A Caccamo, 2010, Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments, J Biol Chem, 285, 13107, 10.1074/jbc.M110.100420 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Hettich, M. M., Matthes, F., Ryan, D. P., Griesche, N., Schröder, S., Dorn, S., Krauß, S., & Ehninger, D.
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2014-07-15
Volume
9
Issue
7
Pages
e102420
ISSN
1932-6203
DOI
10.1371/journal.pone.0102420
PMC
PMC4099345
Cited by
78
References
6
Language
en
Update notices
correction (2014-08-25)
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review